OBJECTIVE: Survival scores can help physicians select appropriate treatment for patients with brain metastasis. Primary tumors have different biological behavior justifying separate scoring systems for different tumors. In this study, a survival score was developed for patients with brain metastasis from SCLC. METHODS: Data of 172 patients receiving whole-brain radiotherapy alone for brain metastasis from SCLC were included. Patients were assigned to a test (N=86) or a validation group (N=86). In the test group, Karnofsky Performance Score, number of brain metastases, and extracranial metastasis were associated with survival and included in the score. Scores for each factor were obtained from the 6-month survival rate divided by 10. According to the total scores, which represented the sum of the three scores, three prognostic groups were formed. RESULTS: 6-Month survival rates in the test group were 3% for 5-8 points, 40% for 9-12 points, and 89% for 15 points (p<0.001). In the validation group, 6-month survival rates were 3%, 41%, and 89% (p<0.001). The comparisons between the three prognostic groups of the test group and the validation group did not show significant differences. CONCLUSIONS: This new score appears valid and reproducible. It can be used to personalize the treatment to patients with brain metastasis from SCLC.
OBJECTIVE: Survival scores can help physicians select appropriate treatment for patients with brain metastasis. Primary tumors have different biological behavior justifying separate scoring systems for different tumors. In this study, a survival score was developed for patients with brain metastasis from SCLC. METHODS: Data of 172 patients receiving whole-brain radiotherapy alone for brain metastasis from SCLC were included. Patients were assigned to a test (N=86) or a validation group (N=86). In the test group, Karnofsky Performance Score, number of brain metastases, and extracranial metastasis were associated with survival and included in the score. Scores for each factor were obtained from the 6-month survival rate divided by 10. According to the total scores, which represented the sum of the three scores, three prognostic groups were formed. RESULTS: 6-Month survival rates in the test group were 3% for 5-8 points, 40% for 9-12 points, and 89% for 15 points (p<0.001). In the validation group, 6-month survival rates were 3%, 41%, and 89% (p<0.001). The comparisons between the three prognostic groups of the test group and the validation group did not show significant differences. CONCLUSIONS: This new score appears valid and reproducible. It can be used to personalize the treatment to patients with brain metastasis from SCLC.
Authors: Dirk Rades; Stefan Huttenlocher; Liesa Dziggel; Mai Trong Khoa; Pham Van Thai; Dagmar Hornung; Steven E Schild Journal: Lung Date: 2014-12-21 Impact factor: 2.584
Authors: Dirk Rades; Stefan Janssen; Liesa Dziggel; Oliver Blanck; Amira Bajrovic; Theo Veninga; Steven E Schild Journal: BMC Cancer Date: 2017-01-06 Impact factor: 4.430
Authors: Denise Bernhardt; Adriane Hommertgen; Daniela Schmitt; Rami El Shafie; Angela Paul; Laila König; Johanna Mair-Walther; Johannes Krisam; Christina Klose; Thomas Welzel; Juliane Hörner-Rieber; Jutta Kappes; Michael Thomas; Claus Peter Heußel; Martin Steins; Meinhard Kieser; Jürgen Debus; Stefan Rieken Journal: Trials Date: 2018-07-16 Impact factor: 2.279